Barinthus Biotherapeutics (BRNS) Total Liabilities (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Total Liabilities came in at $25.7 million in Q1 2026, down 2.8% YoY from $26.4 million in Q1 2025, and up 7.49% on a QoQ basis from $23.9 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Total Liabilities (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Total Liabilities data on file, last reported at $25.7 million in Q1 2026.
- Quarterly Total Liabilities fell 2.8% year-over-year to $25.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.7 million (down 2.8% YoY) and the FY2025 annual result came in at $23.9 million, down 20.92% from the prior year.
- Total Liabilities climbed to $25.7 million in Q1 2026, from $23.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $34.4 million in Q3 2023 to a low of $23.9 million in Q4 2025.
- A 5-year average of $28.5 million and a median of $28.2 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 227.08% — and 2025, when it decreased 20.92%.
- Tracing BRNS's Total Liabilities over 5 years: stood at $27.0 million in 2022, then increased by 1.88% to $27.5 million in 2023, then gained by 9.75% to $30.2 million in 2024, then declined by 20.92% to $23.9 million in 2025, then rose by 7.49% to $25.7 million in 2026.
- The last three Total Liabilities figures came in at $25.7 million (Q1 2026), $23.9 million (Q4 2025), and $24.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 24.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.76 Mn |
| Mar 31, 2026 | 25.67 Mn |
| Dec 31, 2025 | 23.88 Mn |
| Sep 30, 2025 | 24.64 Mn |
| Jun 30, 2025 | 27.08 Mn |
| Mar 31, 2025 | 26.40 Mn |
| Dec 31, 2024 | 30.19 Mn |
| Sep 30, 2024 | 29.23 Mn |
| Jun 30, 2024 | 29.96 Mn |
| Mar 31, 2024 | 27.47 Mn |
| Dec 31, 2023 | 27.51 Mn |
| Sep 30, 2023 | 34.37 Mn |
| Jun 30, 2023 | 28.67 Mn |
| Mar 31, 2023 | 28.25 Mn |
| Dec 31, 2022 | 27.00 Mn |
| Sep 30, 2022 | 31.33 Mn |
| Jun 30, 2022 | 30.29 Mn |
| Mar 31, 2022 | 32.99 Mn |
| Dec 31, 2021 | 28.15 Mn |
| Sep 30, 2021 | 14.10 Mn |